This week we have the results from our GLP-1 Survey. Thanks to the great number of you who participated, and congratulations to Dr. Donald W., of Southern Pines, North Carolina, the winner of our Kindle/Nook giveaway.

As we put together the original survey, our first thoughts were to find out what you wanted to know about GLP-1 analogs, and what your impressions of this class of drugs are. Click here to find out what your colleagues had to say.

Many of you have your own opinions on GLP-1 analogs. We thought you might like to hear how Dr. Aaron Vinik, Director, EVMS Strelitz Diabetes Research Center, uses GLP-1 analogs in his practice, and why and how he selects the patients for GLP-1 analog therapy.

And after you have read the first two features, be sure to review the case of A Caucasian Man with Newly Diagnosed Type 2 Diabetes and Renal Insufficiency, Part 1.

This week we have some results from our GLP-1 survey. Thanks to the great number of you who participated. As we put together the original survey our first thoughts were to find out what you wanted to know about GLP-1 analogs and what your impressions of the class of drugs are. We asked you "what were the most important things you wanted to know about this class of drugs?" and found that, overall, the top five, in order of preference, were....

Case Presentation, Part 1: Mr. Walker is a 59-year-old Caucasian who presents for evaluation of his type 2 diabetes, discovered 6 months ago by a random glucose measurement of 250 mg/dL using his wife's blood glucose meter. Mr. Walker visited his physician a few days later at his wife's request and had an A1C measurement of 7.5%....

One of the leading diabetes researchers in the world, Dr. Aaron I. Vinik leads the EVMS Strelitz Diabetes Center's quest to cure diabetes. Internationally renowned for his research in the areas of hormone secreting tumors and the chronic complications of diabetes, Dr. Vinik has presented his work all over the world....

Lyxumia (lixisenatide) when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia....

Once-Daily Lixisenatide meets primary efficacy endpoint with fewer hypoglycemias than Exenatide twice-daily....

TransPharma Medical, Ltd., announced the successful completion of a Phase 1a trial of ViaDerm-GLP1 agonist which is being developed for the treatment of Type 2 diabetes....